A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

NCT03557411 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: SHR-1210

Sponsor

Shandong Cancer Hospital and Institute

Collaborators

[object Object]